- ISIN
- US74340E1038
- CUSIP
- 74340E103
- Sector
- Healthcare
- Industry
- Health Information Services
- IPO Date
- Oct 25, 2019
Highlights
- Market Cap
- $2.23B
- Enterprise Value
- $2.12B
- EPS (TTM)
- $0.76
- PE Ratio
- 34.37
- PEG Ratio
- 2.89
- Total Revenue (TTM)
- $1.29B
- Gross Profit (TTM)
- $311.76M
- EBITDA (TTM)
- $108.11M
- Year Range
- $16.10 - $28.75
- Target Price
- $30.80
- ROA (TTM)
- 9.69%
- ROE (TTM)
- 15.41%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PGNY Performance Chart
Progyny, Inc. (PGNY) is up 2.3% since the beginning of the year. At $26 per share, PGNY is trading 8.6% below its 52-week high of $29. Investors who bought $1,000 worth of PGNY shares 5 years ago would now be looking at an investment worth $440.
Loading charts...
Returns By Period
Progyny, Inc. (PGNY) has returned 2.34% so far this year and 25.26% over the past 12 months.
Progyny, Inc.
- 1D
- 0.77%
- 1M
- 5.63%
- YTD
- 2.34%
- 6M
- -2.52%
- 1Y
- 25.26%
- 3Y*
- -10.45%
- 5Y*
- -15.15%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PGNY Monthly Returns History
Based on dividend-adjusted daily data since Oct 25, 2019, PGNY's average daily return is +0.12%, while the average monthly return is +2.08%. At this rate, an investment would double in approximately 2.8 years.
Historically, 56% of months were positive and 44% were negative. The best month was Nov 2019 with a return of +62.1%, while the worst month was Sep 2024 at -28.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, PGNY closed higher 51% of trading days. The best single day was Aug 5, 2022 with a return of +38.2%, while the worst single day was Sep 19, 2024 at -32.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.05% | -25.89% | -4.01% | 9.42% | 37.57% | 2.82% | 2.34% | ||||||
| 2025 | 34.32% | -2.76% | -0.84% | 2.24% | -5.87% | 2.33% | 6.86% | 0.68% | -9.08% | -13.06% | 40.94% | -2.62% | 48.87% |
| 2024 | 2.45% | -4.12% | 4.46% | -15.96% | -15.94% | 6.16% | -1.43% | -16.70% | -28.65% | -10.20% | 3.46% | 10.79% | -53.60% |
| 2023 | 10.40% | 9.22% | -14.48% | 3.49% | 12.06% | 5.61% | 6.15% | -10.58% | -8.89% | -9.29% | 11.34% | 8.21% | 19.36% |
| 2022 | -19.56% | -2.81% | 30.59% | -25.19% | -17.79% | -8.10% | 5.09% | 31.71% | -7.83% | 19.99% | -17.63% | -14.96% | -38.13% |
| 2021 | 10.33% | -10.01% | 5.75% | 27.86% | 12.53% | -7.87% | -5.61% | 0.32% | 0.23% | 9.70% | -17.35% | -0.83% | 18.78% |
Benchmark Metrics
Progyny, Inc. has an annualized alpha of 10.76%, beta of 1.20, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since October 25, 2019.
- This stock participated in 138.26% of S&P 500 Index downside but only 126.72% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.76%
- Beta
- 1.20
- R²
- 0.15
- Upside Capture
- 126.72%
- Downside Capture
- 138.26%
Return for Risk
Risk / Return Rank
PGNY ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Progyny, Inc. (PGNY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PGNY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.58 | ||
| Sortino ratioReturn per unit of downside risk | -1.65 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.37 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | 0.60 | 2.78 | -2.19 |
| Martin ratioReturn relative to average drawdown | 1.27 | 12.44 | -11.17 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Progyny, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Progyny, Inc. was 79.49%, occurring on Nov 19, 2024. The portfolio has not yet recovered.
The current Progyny, Inc. drawdown is 60.58%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -79.49%Nov 2024 | 3y 11d | — | 4y 7moNov 2021 - now |
COVID crash2020 | -53.74%Mar 2020 | 1mo 3d | 8mo 9d | 9mo 12dFeb 2020 - Nov 2020 |
2021 bear market2021 | -33.13%Aug 2021 | 2mo 10d | 2mo 23d | 5mo 3dJun 2021 - Nov 2021 |
2021 bear market2021 | -23.77%Mar 2021 | 7d | 1mo 23d | 2moFeb 2021 - Apr 2021 |
2019 bear market2019 | -22.79%Dec 2019 | 11d | 24d | 1mo 5dDec 2019 - Jan 2020 |
Drawdown Indicators
| PGNY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.49% | -56.78% | -22.71% |
Max Drawdown (1Y)Largest decline over 1 year | -42.65% | -9.10% | -33.55% |
Max Drawdown (3Y)Largest decline over 3 years | -68.14% | -18.90% | -49.24% |
Max Drawdown (5Y)Largest decline over 5 years | -79.49% | -25.43% | -54.06% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -60.58% | -1.80% | -58.78% |
Average DrawdownAverage peak-to-trough decline | -42.48% | -10.71% | -31.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.90% | 2.03% | +17.87% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Progyny, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Progyny, Inc. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for PGNY, comparing it with other companies in the Health Information Services industry. Currently, PGNY has a P/E ratio of 34.4. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for PGNY compared to other companies in the Health Information Services industry. PGNY currently has a PEG ratio of 2.9. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PGNY relative to other companies in the Health Information Services industry. Currently, PGNY has a P/S ratio of 1.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PGNY in comparison with other companies in the Health Information Services industry. Currently, PGNY has a P/B value of 5.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PGNY
Add Progyny, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PGNY